A university spinout was developing oligonucleotide therapeutics to address age-related disorders. The company wanted to understand the most attractive lead indications in which to focus its preclinical and clinical development programs and had already short-listed 25 indications as a starting point. Alacrita conducted a comprehensive indication prioritization exercise to identify the top five indications.
Alacrita first conducted a reality check on the clients’ proposed indication prioritization scoring criteria. We implemented go/no-go criteria to filter out any non-viable indications.
Our expert team then carried out an extensive literature review on each short-listed indication, assessing both clinical and commercial aspects to allow for criteria scoring.
The indications were scored and the top five indications that passed the go/no-go criteria were identified. These priority indications were in-line with client expectations and integrated into future development plans.
Our team of pharma business consultants provide deep knowledge in critical areas such as company and portfolio strategies, fundraising pitch materials, platform or program opportunity-feasibility assessments, new product planning, value-based pricing and market access, and product launch preparations.